Ephicacy's Strategic Power Play: New Leaders to Drive AI and Global Scale in Clinical Trials

ISELIN, NJ – March 23, 2026 – Ephicacy, a specialized biometrics contract research organization (CRO), has announced two pivotal leadership appointments, signaling a major strategic push to dominate the rapidly evolving landscape of clinical trial data analytics. The company has named Jamie Powers, DrPH, as Senior Vice President of Biometrics and appointed Tyagrajan “Tyagi” Swaminathan as Head of India Operations and Vice President of Statistical Programming.

These moves are far more than a routine corporate shuffle. They represent a calculated response to the pharmaceutical and biotechnology industries' immense pressure to make drug development faster, more efficient, and more predictable. By installing proven leaders in advanced analytics and global operations, Ephicacy is positioning itself to lead the charge in a sector increasingly reliant on artificial intelligence (AI), real-world evidence (RWE), and globally integrated service delivery.

Bolstering Biometrics with Advanced Analytics Expertise

The appointment of Jamie Powers places a seasoned expert in advanced analytics at the helm of Ephicacy’s Project-Based Services (PBS) unit, which encompasses data management, biostatistics, and statistical programming. With over 23 years of experience, Powers' resume reads like a who's who of data-driven life sciences, with leadership roles at industry giants like IQVIA, Takeda Pharmaceutical Company, SAS Institute, and ConcertAI.

Her expertise is particularly critical in the areas of AI and RWE, two of the most transformative forces in modern medicine. The pharmaceutical industry is drowning in data, from clinical trial results to electronic health records and wearable device outputs. The challenge is no longer just collecting data, but interpreting it to generate actionable insights. This is where Powers' background becomes a significant asset. Her DrPH (Doctor of Public Health) provides a deep-seated foundation in biostatistics and epidemiology, the very bedrock of clinical research.

"Jamie’s expertise in advanced analytics, real-world evidence, and biostatistics aligns strongly with the evolving needs of modern clinical trials," said CEO Tara Gladwell in a statement. "His cross-industry experience will help expand our biometrics capabilities and strengthen the value we deliver to clients."

The industry context underscores the significance of this hire. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly open to using RWE to support drug approvals and monitor post-market safety. This shift demands a sophisticated understanding of how to collect, curate, and analyze real-world data ethically and effectively. Powers' experience is set to directly address this growing client need, potentially expanding Ephicacy’s consulting and analytics services into more complex RWE study designs and regulatory submissions.

Strengthening the Global Delivery Engine in India

Concurrently, the elevation of Tyagrajan “Tyagi” Swaminathan to Head of India Operations and VP of Statistical Programming fortifies the engine room of Ephicacy’s global delivery model. In the world of CROs, India has become an indispensable hub for biometrics and data services, and for good reason. The country offers a vast, highly-educated talent pool in statistics and programming, significant cost efficiencies, and a time-zone advantage that enables a 24/7 "follow-the-sun" workflow for global projects.

Swaminathan’s appointment is a strategic move to reinforce and expand this critical operational base. As major competitors like IQVIA and Labcorp also maintain substantial operations in India, ensuring strong, experienced leadership on the ground is not just beneficial—it's essential for competitive survival and growth. CEO Tara Gladwell recognized this by highlighting Swaminathan's "leadership in building high-performing teams and advancing our global delivery model."

His role is twofold: ensuring the massive statistical programming and data management teams in India operate with maximum efficiency and quality, and scaling those operations to meet rising demand. For pharmaceutical clients, this translates into faster data processing, quicker turnaround times on analysis, and the assurance that their complex, global trials are supported by a robust and reliable operational backbone.

A Synergistic Strategy for Market Leadership

Viewed together, the appointments of Powers and Swaminathan reveal a cohesive, two-pronged strategy. Ephicacy is simultaneously sharpening the cutting edge of its analytical capabilities while reinforcing the operational horsepower needed to deliver those services at scale. It is a classic synergy play: Powers' team will design the sophisticated analytical models and RWE strategies, and Swaminathan’s teams will provide the scalable programming and data management muscle to execute them efficiently across the globe.

This integrated approach allows the Iselin-based CRO to offer a compelling value proposition. It can compete with the advanced analytics boutiques on innovation while rivaling the scale and efficiency of the biometrics divisions within much larger CROs. For a mid-sized, specialized firm, this dual focus is a powerful differentiator.

The appointments reflect the company’s "continued investment in scaling biometrics and analytics capabilities as demand grows for advanced statistical programming and data science in clinical development," according to its official announcement. This investment is aimed squarely at helping clients navigate the complexities of modern drug development.

Redefining the Future of Clinical Trial Execution

Ultimately, the impact of these leadership changes will be measured by the value delivered to Ephicacy's pharmaceutical and biotechnology clients. The goal is to move beyond traditional data processing and become a strategic partner that helps make clinical trials more predictable and less costly.

With Powers' guidance, the company is poised to develop more sophisticated AI-driven predictive models to optimize trial design, improve patient recruitment, and identify potential safety signals earlier in the process. Her focus on RWE could unlock new pathways for demonstrating product value and satisfying regulatory requirements, potentially accelerating market access for new therapies.

"I am excited to join Ephicacy at a time when data science and AI are transforming clinical development,” Powers stated. “I look forward to strengthening our biometrics capabilities, advancing more predictable and efficient trial execution, and helping our clients unlock greater value from their data.”

This vision, combined with Swaminathan's mandate to optimize the global delivery framework, positions Ephicacy not just to participate in the future of clinical analytics, but to actively shape it. By wedding high-level strategic insight with operational excellence, the company is making a bold statement about its ambition to be an indispensable partner in bringing new medicines to patients faster.